Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Stock Information for Sonnet BioTherapeutics Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sonnet BioTherapeutics Holdings Inc.

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.